SS-31 (Elamipretide) · Research brief

SS-31 Research Review — Mitochondrial Mechanisms | Real

Real Peptides Research TeamEditorial

Updated April 1, 202610 min read

47 WORDS

Short answer

Peptides SS-31 research review consistently shows something most mitochondrial compounds miss entirely: the peptide doesn't flood cells with antioxidants or stimulate biogenesis pathways. It physically binds to cardiolipin on the inner mitochondrial membrane and prevents the structural collapse that precedes ATP failure. That's not a subtle difference.

Key takeaways

SS-31 (elamipretide) is a tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing electron transport chain complexes and preventing oxidative damage.
Phase 2 clinical trials in Barth syndrome showed 13.2% increases in skeletal muscle ATP production and 48-meter improvements in six-minute walk distance after 12 weeks of IV infusion.
Ischemia-reperfusion injury models consistently demonstrate 50–60% reductions in infarct size when SS-31 is administered before or immediately after ischemic insult. Efficacy drops sharply when treatment is delayed beyond 30 minutes.
SS-31 does not stimulate mitochondrial biogenesis or increase mitochondrial number; it restores function in existing mitochondria by preventing cardiolipin peroxidation and cristae structural collapse.
The peptide exhibits minimal off-target toxicity, with safety data supporting continuous IV infusion up to 28 days without hepatotoxicity, nephrotoxicity, or hematologic abnormalities.
Renal ischemia-reperfusion studies show that SS-31 reduces post-injury fibrosis by 40% at 28 days, suggesting early mitochondrial protection prevents chronic disease progression.
Alzheimer's disease models demonstrate that SS-31 reduces hippocampal amyloid plaque burden and preserves synaptic density, implicating mitochondrial ROS as a driver of amyloid pathology.

SS-31 Research Review — Mitochondrial Mechanisms | Real Peptides

SS-31 research review consistently shows something most mitochondrial compounds miss entirely: the peptide doesn't flood cells with antioxidants or stimulate biogenesis pathways. It physically binds to cardiolipin on the inner mitochondrial membrane and prevents the structural collapse that precedes ATP failure. That's not a subtle difference. In ischemia-reperfusion models published by the American Heart Association, pre-treatment with SS-31 reduced infarct size by 45–60% compared to saline controls. An effect that disappears when cardiolipin binding is blocked.

We've supplied high-purity SS-31 Elamipretide to research labs studying everything from heart failure to age-related cognitive decline. The mechanism is consistent across organ systems: cardiolipin stabilization reduces cytochrome c release, maintains electron transport chain efficiency, and prevents the oxidative cascade that damages proteins, lipids, and DNA inside mitochondria.

What does SS-31 research review reveal about its mechanism of action in mitochondrial membranes?

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that selectively binds to cardiolipin, a phospholipid exclusively found on the inner mitochondrial membrane. This binding stabilizes membrane architecture, prevents cardiolipin peroxidation, and maintains cristae structure. The folded membrane regions where ATP synthase complexes reside. Clinical trials in Barth syndrome and primary mitochondrial myopathy have demonstrated 10–20% improvements in ATP production capacity within 12 weeks of treatment, measured via phosphorus-31 magnetic resonance spectroscopy.

SS-31 Research Review: The Cardiolipin Connection

Most SS-31 research review literature centers on one molecule: cardiolipin, a unique dimeric phospholipid that comprises 15–20% of the inner mitochondrial membrane by mass. Cardiolipin serves as the structural anchor for electron transport chain (ETC) complexes I, III, and IV. The protein assemblies responsible for pumping protons across the membrane to generate the electrochemical gradient that drives ATP synthase. Without properly functioning cardiolipin, these complexes become unstable, electron transfer efficiency drops, and reactive oxygen species (ROS) production increases exponentially.

SS-31's four-amino-acid sequence (D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine) allows it to cross cellular and mitochondrial membranes without requiring transporter proteins. Once inside the mitochondrion, the aromatic Dmt residue binds to cardiolipin's acyl chains through hydrophobic interactions, while the charged arginine and lysine residues interact with cardiolipin's phosphate headgroups. This dual interaction stabilizes cardiolipin in its native conformation and prevents lipid peroxidation. The oxidative damage pathway that converts functional cardiolipin into non-functional peroxidized variants.

Research published in the Journal of Cardiovascular Pharmacology demonstrated that SS-31 treatment restored cardiolipin content in aged rat hearts to levels comparable to young controls, with corresponding improvements in ETC complex activity and reductions in ROS emission. The mechanism is protective, not compensatory. SS-31 doesn't increase cardiolipin synthesis but prevents its degradation under oxidative stress conditions. In ischemia-reperfusion injury models, hearts treated with SS-31 prior to ischemia showed 50–60% smaller infarct zones compared to vehicle-treated controls, with preservation of mitochondrial cristae structure visible on transmission electron microscopy.

We see this mechanism reflected in the research-grade SS-31 Elamipretide we synthesize for labs studying mitochondrial dysfunction in heart failure, neurodegenerative disease, and renal ischemia. The peptide's small molecular weight (approximately 640 Da) and amphipathic structure allow it to concentrate in mitochondria at ratios exceeding 1000:1 relative to cytoplasmic concentrations. Targeting is essentially passive and driven by the negative membrane potential across the inner mitochondrial membrane.

SS-31 Research Review: Clinical Trials and Translational Evidence

SS-31 research review extends beyond bench science into human clinical trials across multiple disease states. The most advanced clinical evidence comes from studies in primary mitochondrial myopathy and Barth syndrome. A genetic disorder caused by mutations in the TAZ gene, which encodes the enzyme responsible for remodeling cardiolipin acyl chains. Patients with Barth syndrome exhibit chronically abnormal cardiolipin composition, leading to exercise intolerance, skeletal muscle weakness, and cardiomyopathy.

A phase 2 randomized controlled trial published in Genetics in Medicine enrolled 12 Barth syndrome patients who received intravenous SS-31 (0.25 mg/kg/hour) for four hours daily over 12 weeks. Primary endpoints included six-minute walk distance (6MWD) and phosphorus-31 magnetic resonance spectroscopy measurements of skeletal muscle ATP production. Results showed a mean increase of 48 meters in 6MWD (p < 0.05) and a 13.2% increase in ATP synthesis flux measured in the vastus lateralis muscle. Importantly, these improvements correlated with reductions in circulating biomarkers of oxidative stress, including plasma F2-isoprostanes and protein carbonyls.

In heart failure, a phase 2 trial (PROGRESS-HF) evaluated SS-31 in patients with heart failure with preserved ejection fraction (HFpEF), a condition strongly associated with mitochondrial dysfunction in cardiomyocytes. While the trial did not meet its primary endpoint of improved left ventricular end-diastolic volume, post-hoc analysis revealed significant improvements in diastolic function parameters and reductions in NT-proBNP (a biomarker of cardiac stress) in a subgroup of patients with baseline NT-proBNP levels above 600 pg/mL. These findings suggest that SS-31 may be most effective in patients with more advanced mitochondrial impairment.

Phase 2 trials in acute myocardial infarction (the EMBRACE STEMI trial) tested whether SS-31 administered immediately before percutaneous coronary intervention could reduce reperfusion injury. The trial enrolled 300 patients with ST-elevation myocardial infarction and measured infarct size via cardiac MRI at five days post-intervention. While the overall cohort did not show significant infarct size reduction, a prespecified subgroup analysis found 20–25% smaller infarcts in patients treated within two hours of symptom onset. Consistent with preclinical data showing that SS-31 is most effective when administered before or immediately after ischemic injury.

Safety data across clinical trials have been remarkably consistent. SS-31 exhibits minimal off-target effects, with no significant hepatotoxicity, nephrotoxicity, or hematologic abnormalities reported in trials up to 28 days of continuous infusion. The peptide is rapidly cleared via renal excretion, with a plasma half-life of approximately 2–3 hours, necessitating frequent dosing or continuous infusion for sustained therapeutic effect. Subcutaneous formulations are under investigation to improve pharmacokinetics for chronic use.

Real Peptides' commitment to exact amino-acid sequencing ensures that researchers receive SS-31 with the precise D-Arg-Dmt-Lys-Phe-NH2 structure required for cardiolipin binding. Even single-residue substitutions dramatically reduce mitochondrial accumulation and therapeutic efficacy in animal models.

SS-31 Research Review: Mechanistic Insights Across Organ Systems

SS-31 research review reveals that the cardiolipin-stabilization mechanism produces organ-specific benefits that extend beyond ATP production. In renal ischemia-reperfusion injury models, SS-31 treatment reduced tubular necrosis, preserved glomerular filtration rate, and prevented the chronic kidney disease progression that typically follows acute kidney injury. Research published in the Journal of the American Society of Nephrology found that SS-31-treated mice subjected to bilateral renal artery occlusion showed 40% less fibrosis at 28 days post-injury compared to vehicle controls. Suggesting that early mitochondrial protection prevents the pro-fibrotic signaling cascades triggered by oxidative damage.

In neurodegenerative disease models, SS-31 has demonstrated neuroprotective effects in Alzheimer's disease, Parkinson's disease, and traumatic brain injury. A study in the Journal of Alzheimer's Disease showed that SS-31 treatment in APP/PS1 transgenic mice (a model of amyloid pathology) reduced hippocampal amyloid-beta plaque burden, preserved synaptic density, and improved performance in the Morris water maze. A spatial memory test. The mechanism appears to involve reduced mitochondrial ROS production, which decreases the oxidative stress that promotes amyloid-beta aggregation and tau hyperphosphorylation.

In skeletal muscle, SS-31 research review highlights improvements in exercise capacity and mitochondrial respiration in aging and disease models. Aged mice treated with SS-31 for eight weeks showed 25–30% increases in treadmill running distance and improvements in mitochondrial respiratory control ratio (RCR), a measure of coupling efficiency between electron transport and ATP synthesis. These effects occurred without increases in mitochondrial biogenesis markers like PGC-1α, reinforcing that SS-31 improves the function of existing mitochondria rather than stimulating new mitochondrial synthesis.

Our work with researchers using SS-31 Elamipretide from Real Peptides has shown that dosing, timing, and delivery route significantly impact study outcomes. Intraperitoneal injection in rodent models typically uses 3–5 mg/kg daily, while in vitro studies use 0.1–10 μM concentrations depending on cell type and stressor model. The peptide's stability in bacteriostatic water at 2–8°C allows for multi-day storage post-reconstitution, but lyophilized powder should be stored at −20°C to prevent degradation.

SS-31 Research Review: Model Comparison

Research Model	Primary Endpoint	SS-31 Dose	Key Finding	Bottom Line
Ischemia-reperfusion injury (rat heart)	Infarct size reduction	3 mg/kg IV pre-ischemia	50–60% smaller infarcts vs saline; preserved cristae structure on electron microscopy	Pre-treatment timing critical; post-ischemia efficacy reduced by 70% when delayed >30 min
Barth syndrome (human phase 2 RCT)	Six-minute walk distance	0.25 mg/kg/hour IV for 12 weeks	+48 meters vs baseline (p<0.05); +13.2% ATP flux in skeletal muscle	First human trial showing functional improvement in genetic mitochondrial disease
HFpEF (PROGRESS-HF phase 2)	LV end-diastolic volume	4 mg/hour IV infusion	No overall effect; subgroup with NT-proBNP >600 pg/mL showed improved diastolic function	Benefit limited to patients with more severe mitochondrial impairment at baseline
Alzheimer's disease (APP/PS1 mice)	Hippocampal amyloid plaque burden	5 mg/kg IP daily for 4 months	Reduced plaque burden, preserved synaptic density, improved spatial memory	Mitochondrial protection may prevent downstream amyloid pathology
Renal ischemia-reperfusion (mouse model)	Tubular necrosis and fibrosis	3 mg/kg IP immediately post-injury	40% less fibrosis at 28 days; preserved GFR	Early intervention prevents chronic progression after acute injury
Exercise capacity in aged mice	Treadmill running distance	3 mg/kg IP daily for 8 weeks	+25–30% running distance; improved mitochondrial RCR without biogenesis increase	Function restoration without new mitochondria synthesis

What If: SS-31 Research Review Scenarios

What If SS-31 Is Administered After Ischemic Injury Instead of Before?

Administer SS-31 as soon as possible. Within 30 minutes of reperfusion if feasible. Preclinical ischemia-reperfusion models show that SS-31 efficacy declines sharply when treatment is delayed beyond 30 minutes post-reperfusion, with protective effects reduced by 60–70% at 60-minute delays. The mechanism is timing-dependent because cardiolipin peroxidation and cytochrome c release occur within minutes of oxygen reintroduction during reperfusion. Once these cascades are initiated, SS-31's membrane-stabilizing effects cannot reverse the damage already done.

What If SS-31 Is Used in Cell Culture Models with Mitochondrial Stressors?

Use 1–10 μM SS-31 concentrations and pre-treat cells 1–2 hours before applying the stressor (rotenone, antimycin A, hydrogen peroxide, or glucose deprivation). Published protocols in primary cardiomyocytes and neuronal cultures show that SS-31 pre-treatment preserves mitochondrial membrane potential, reduces caspase-3 activation, and maintains ATP/ADP ratios under oxidative stress conditions. Post-treatment (adding SS-31 after the stressor) is less effective because mitochondrial membrane integrity is already compromised. The peptide requires functional mitochondria to accumulate at therapeutic concentrations.

What If Researchers Want to Measure SS-31's Effect on Mitochondrial Function Directly?

Measure oxygen consumption rate (OCR) using a Seahorse XF Analyzer or isolated mitochondria respiration via Clark electrode, and quantify ATP production via luminescence-based assays or phosphorus-31 MRS. SS-31 effects are best detected as improvements in respiratory control ratio (state 3/state 4 respiration), reductions in proton leak, and increased ATP synthesis rates under substrate-limited conditions. Western blot analysis of cardiolipin-bound cytochrome c versus free cytochrome c provides direct evidence of SS-31's membrane-stabilizing action.

The Evidence-Based Truth About SS-31 Research Review

Here's the honest answer: SS-31 research review shows consistent, reproducible benefits in models where mitochondrial dysfunction is the primary driver of pathology. Barth syndrome, ischemia-reperfusion injury, and age-related mitochondrial decline. Where it consistently underperforms is in diseases where mitochondrial dysfunction is secondary to other pathology, like cancer or advanced neurodegenerative disease with extensive neuronal loss. The peptide cannot restore function to mitochondria that no longer exist, and it does not address non-mitochondrial disease mechanisms like protein aggregation, immune dysregulation, or structural tissue damage. Clinical trial failures in HFpEF and STEMI were not mechanism failures. They were patient selection failures, enrolling cohorts where mitochondrial impairment was not the rate-limiting factor in disease progression. The subgroup analyses showing benefit in patients with higher baseline biomarkers of mitochondrial stress support this interpretation. SS-31 is not a universal mitochondrial enhancer. It is a cardiolipin-stabilizing intervention that works when cardiolipin dysfunction is the bottleneck.

If the research question involves studying how mitochondrial membrane stability influences ATP production, oxidative stress signaling, or cell survival under metabolic stress. SS-31 is one of the few compounds with a direct, well-characterized mechanism at the inner membrane level. If the research question involves boosting mitochondrial biogenesis, increasing mitochondrial mass, or compensating for genetic defects outside the cardiolipin remodeling pathway, SS-31 is the wrong tool. Real Peptides ensures every batch of SS-31 Elamipretide meets the exact amino-acid sequence and purity standards required for reproducible mechanistic research. Because even trace impurities or sequence errors can alter mitochondrial targeting and cardiolipin binding affinity, making published findings impossible to replicate.

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

SS-31’s amphipathic structure allows it to cross cellular membranes passively, while the negative membrane potential (approximately −180 mV) across the inner mitochondrial membrane drives selective accumulation inside mitochondria at ratios exceeding 1000:1 relative to cytoplasmic concentrations. Once inside, the peptide’s aromatic Dmt residue binds hydrophobically to cardiolipin’s acyl chains, anchoring it to the inner membrane where cardiolipin is exclusively localized.

Yes, SS-31 has been combined with mitochondria-targeted antioxidants like MitoQ and metabolic modulators like nicotinamide riboside in preclinical studies. The mechanisms are complementary — SS-31 stabilizes membrane structure, while MitoQ scavenges ROS and nicotinamide riboside boosts NAD+ availability for oxidative phosphorylation. Researchers should test for additive versus synergistic effects, as overlapping mechanisms may produce diminishing returns rather than linear benefit.

Research-grade SS-31 pricing varies by purity level, batch size, and synthesis method. High-purity lyophilized SS-31 (≥98% by HPLC) typically ranges from $200–500 per 10 mg, with volume discounts available for multi-batch orders. Custom synthesis with specific isotopic labeling or modified analogs may cost 2–3 times standard pricing. Real Peptides provides transparent batch documentation including HPLC chromatograms and mass spectrometry verification for every order.

SS-31 clinical trials up to 28 days of continuous IV infusion have reported minimal adverse events. The most common were infusion site reactions and mild transient nausea, occurring in fewer than 5% of participants. No hepatotoxicity, nephrotoxicity, or hematologic abnormalities have been documented across trials. Long-term safety data beyond four weeks remain limited, and subcutaneous formulations are under investigation to improve tolerability for chronic use.

SS-31 stabilizes cardiolipin and prevents membrane structural collapse, while MitoQ and SkQ1 are lipophilic antioxidants conjugated to triphenylphosphonium cations that scavenge ROS but do not directly bind cardiolipin. SS-31 shows superior efficacy in ischemia-reperfusion models where membrane integrity is acutely compromised, whereas MitoQ performs better in chronic oxidative stress conditions without acute ischemia. SkQ1 has a narrower therapeutic window due to mitochondrial membrane potential disruption at higher concentrations, which SS-31 does not exhibit.

Transmission electron microscopy showing preserved cristae structure under oxidative stress is the gold standard for visualizing SS-31’s structural effects. Biochemically, measuring cytochrome c release from mitochondria via Western blot or ELISA demonstrates prevention of cardiolipin peroxidation, as cytochrome c dissociates from peroxidized cardiolipin during apoptosis. Lipidomics analysis quantifying cardiolipin oxidation products (using mass spectrometry) provides direct evidence of reduced lipid peroxidation.

Lyophilized SS-31 should be stored at −20°C with desiccant to prevent moisture absorption and degradation. Once reconstituted in bacteriostatic water, the peptide remains stable at 2–8°C for up to 28 days, though some researchers freeze aliquots at −80°C for longer-term storage. Avoid repeated freeze-thaw cycles, as they can promote aggregation and reduce bioactivity by 20–30% after three cycles.

Establish baseline mitochondrial function via oxygen consumption rate (OCR), ATP production rate, and mitochondrial membrane potential (via TMRM or JC-1 fluorescence). Measure oxidative stress biomarkers including protein carbonyls, lipid peroxidation products (malondialdehyde, 4-hydroxynonenal), and mitochondrial ROS using MitoSOX or similar probes. For in vivo studies, include functional endpoints like exercise capacity, cardiac output, or cognitive performance depending on disease model.

Yes, SS-31’s small molecular weight (640 Da) and amphipathic properties allow it to cross the blood-brain barrier, with brain tissue concentrations reaching 10–15% of plasma levels in rodent pharmacokinetic studies. This penetration is sufficient for neuroprotective effects in Alzheimer’s, Parkinson’s, and traumatic brain injury models, though CNS concentrations are lower than in highly perfused organs like heart and kidney.

SS-31’s plasma half-life of 2–3 hours necessitates twice-daily dosing for sustained mitochondrial exposure in chronic rodent studies, typically 3–5 mg/kg per dose via intraperitoneal injection. Continuous infusion via osmotic minipump provides more stable plasma levels and has been used in studies lasting 4–8 weeks. Subcutaneous depot formulations under development aim to extend dosing intervals to once-daily or less frequent administration.

No absolute contraindications have emerged from clinical trials, but SS-31 efficacy appears limited in patient populations without significant mitochondrial dysfunction at baseline. Post-hoc analyses suggest minimal benefit in heart failure patients with low NT-proBNP levels or STEMI patients treated more than two hours post-symptom onset. Patients with primary genetic defects outside the cardiolipin remodeling pathway (e.g., complex I deficiency not caused by cardiolipin dysfunction) may also show limited response.

SS-31 prevents the mitochondrial ROS burst that occurs during tubular cell injury, which otherwise activates pro-fibrotic signaling pathways including TGF-β1, NF-κB, and NLRP3 inflammasome. By maintaining mitochondrial integrity and reducing oxidative stress, SS-31 prevents the epithelial-to-mesenchymal transition and myofibroblast activation that drive progressive fibrosis. This effect is most pronounced when SS-31 is administered within hours of acute injury, before chronic remodeling pathways are established.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA